Daria B. Crittenden, MD

CymaBay, a Gilead Sciences Company

Poster(s):

• P2931 - Long-Term Efficacy and Safety of Open-Label Seladelpar Treatment in Patients With Primary Biliary Cholangitis: Interim Results for 2 Years From the ASSURE Study
  Monday, October 28, 2024

  10:30 AM – 4:00 PM ET